UK Medicines Information
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Information type:
Randomised controlled trials
Source:
The Lancet
Specialities:
Haematological disorders
Summary
After a median follow-up of 22.9 months, brentuximab vedotin showed improvements over physician's choice for objective global response lasting at least 4 months (56.3% versus 12.5%; p<0.0001) in 131 adults with CD30-expressing relapsed or refractory cutaneous T-cell lymphoma.
UKMi comment
An accompanying editorial discusses these findings.
Related links:
Editorial